Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
Author(s)Kolishetti, Nagesh; Dhar, Shanta; Valencia, Pedro Miguel; Lin, Lucy Q.; Karnik, Rohit; Lippard, Stephen J.; Langer, Robert; Farokhzad, Omid C.; ... Show more Show less
MetadataShow full item record
The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, we describe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we codelivered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH[subscript 3])[subscript 2](O[subscript 2]CCH[subscript 2]CH[subscript 2]COOH)(OH)Cl[subscript 2]] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(d,l-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48–72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.
DepartmentMIT-Harvard Center for Cancer Nanotechnology Excellence; Massachusetts Institute of Technology. Institute for Medical Engineering & Science; Massachusetts Institute of Technology. Department of Chemical Engineering; Massachusetts Institute of Technology. Department of Chemistry; Massachusetts Institute of Technology. Department of Mechanical Engineering; Koch Institute for Integrative Cancer Research at MIT
Proceedings of the National Academy of Sciences of the United States of America
National Academy of Sciences (U.S.)
Kolishetti, N., S. Dhar, P. M. Valencia, et al. Engineering of Self-assembled Nanoparticle Platform for Precisely Controlled Combination Drug Therapy. Proceedings of the National Academy of Sciences 107(42): 17939–17944, 2010.
Final published version